Phlogenzym
Phase 3Small molecule
Phlogenzym is one of 6 small molecule programs targeting Thrombophlebitis. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Thrombophlebitis
#DrugCompanyPhaseTrials
1Heparin Sodium
BBaxter Healthcare Corporation
Approved
Coumadin
AAbbott
Approved
Fondaparinux Sodium
GSKApproved
Dalteparin Sodium
PfizerApproved
Activase
RochePhase 1
Phlogenzym
MMucos Pharma GmbH & Co. KG
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Phlogenzym. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMucos Pharma GmbH & Co. KG